297 related articles for article (PubMed ID: 31980592)
21. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
22. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
23. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
[TBL] [Abstract][Full Text] [Related]
24. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
[TBL] [Abstract][Full Text] [Related]
25. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.
Lambert A; Salleron J; Lion M; Rouyer M; Lozano N; Leroux A; Merlin JL; Harlé A
Pathol Oncol Res; 2019 Jul; 25(3):1117-1123. PubMed ID: 30426328
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.
Tharin Z; Richard C; Derangère V; Ilie A; Arnould L; Ghiringhelli F; Boidot R; Ladoire S
Sci Rep; 2023 Mar; 13(1):4467. PubMed ID: 36934165
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
Dumbrava EE; Call SG; Huang HJ; Stuckett AL; Madwani K; Adat A; Hong DS; Piha-Paul SA; Subbiah V; Karp DD; Fu S; Naing A; Tsimberidou AM; Moulder SL; Koenig KH; Barcenas CH; Kee BK; Fogelman DR; Kopetz ES; Meric-Bernstam F; Janku F
ESMO Open; 2021 Oct; 6(5):100230. PubMed ID: 34479035
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
[TBL] [Abstract][Full Text] [Related]
32. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutation associates with improved outcome in breast cancer.
Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W; Moynahan ME
Clin Cancer Res; 2009 Aug; 15(16):5049-59. PubMed ID: 19671852
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
[TBL] [Abstract][Full Text] [Related]
35. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
36. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
37. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
38. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract][Full Text] [Related]
39. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
40. Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients.
Muendlein A; Geiger K; Gaenger S; Dechow T; Nonnenbroich C; Leiherer A; Drexel H; Gaumann A; Jagla W; Winder T; Mayer F; Decker T
Sci Rep; 2021 Mar; 11(1):6761. PubMed ID: 33762647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
